ClinicalTrials.gg
CompletedNCT04075604CheckMate 7A8Updated Aug 10, 2022Results posted

A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

A Phase 2 interventional study of Nivolumab and Anastrozole in Breast Cancer and Cancer, sponsored by Bristol-Myers Squibb. Completed at 36 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-10.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing nivolumab in Breast Neoplasms — 1 open to participants now, 8 under way, none of them phase 3. Nivolumab · Breast Neoplasms.

Enrollment
16th of 22
23 · median 47
Started
2019
with 9 others
Phase 2
15 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
2 of 22
Bristol-Myers Squibb

Among the 22 studies testing nivolumab in Breast Neoplasms, this one is the 16th largest by enrollment, is one of 10 that started in 2019, is one of 15 in phase 2, and was the 21st registered.

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 22 studies testing nivolumab in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing nivolumab in Breast Neoplasms, or all of them as a file.
02

Study summary

A randomized multi-arm study evaluating the safety and efficacy of palbociclib and anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer

03

Conditions studied

  • Breast Cancer
  • Cancer

Keywords

  • Nivolumab
  • Breast Cancer
  • Cancer
  • ER+
  • HER2-
  • Neoadjuvant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.

Inclusion criteria

Inclusion Criteria:

  • Participants must have untreated, unilateral, confirmed ER+, - invasive breast cancer with primary tumor ≥2 cm in largest diameter (cT1-3) in one dimension by clinical or radiographic exam, for whom endocrine monotherapy deemed to be a suitable therapy.
  • Participants must be deemed eligible for surgery and must agree to undergo surgery after completion of neoadjuvant therapy and agree to provide tumor tissue at baseline, on-treatment, and at surgery.
  • Women must have documented proof that they are not of .
  • Participants must have a performance status (PS) ≤ 1 on the (ECOG) scale

Exclusion criteria

Exclusion Criteria:

  • Participants who may have had any treatment, including radiotherapy, chemotherapy, and/or targeted therapy administered for the currently diagnosed breast cancer prior to enrollment or for whom upfront chemotherapy is clinically judged appropriate as optimal treatment.
  • Participants who have a history of or active, known or suspected disease, or other syndrome that requires systemic above physiological replacement dose or autoimmune agents for the past 2 years.
  • Prior treatment with either ET or CDK4/6 inhibitors for Breast Cancer (BC) within 5 years or an , anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, or history of allergy, or to study drug components
  • Prior active within the previous 3 years or participants with serious or uncontrolled medical disorders.
  • Personal history of any of the following conditions: syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), long or short syndrome, Brugada syndrome, or known history of corrected QT prolongation, Torsade de Pointes, or sudden cardiac arrest.

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Arm A: Nivolumab+Palbociclib+Anastrozole (ANZ)

    Biological: Nivolumab · Drug: Anastrozole · Drug: Palbociclib

  • Experimental
    Arm B: Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ

    Biological: Nivolumab · Drug: Anastrozole · Drug: Palbociclib

  • Active comparator
    Arm C: Palbociclib+ANZ

    Drug: Anastrozole · Drug: Palbociclib

Interventions

06

What researchers measure

Primary outcomes

  1. The Number of Participants With Dose Limiting Toxicities (DLT) in the Safety Run-in Phase

    The number of participants with dose limiting toxicities (DLTs) during the safety run-in phase. DLTS are defined as treatment emergent adverse events (TEAE) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 that occurs during the first 4 weeks (1 cycle) after treatment. Participants who withdraw from the study during the DLT evaluation period or have received less than 1 dose of nivolumab and 75% of accumulative doses of palbociclib of the cycle for reasons other than a DLT will not be considered as DLT-evaluable participants.

    Time frame: From first dose to 4 weeks after first dose

  2. Residual Cancer Burden (RCB) 0-1 Rate in the Randomized Phase

    RCB 0-I rate is defined as the percentage of randomized participants who achieve RCB 0: no residual disease or RCB-I: minimal residual disease. RCB is a continuous index combining pathological measurements of primary tumor (size and cellularity) and nodal metastases (number and size) defined by a point system at surgery. No participants continued to the randomized phase; trial was closed after completion of the Safety Run-in.

    Time frame: From randomization phase up to 5 treatment cycles (up to approximately 20 weeks)

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per investigator radiographic assessment. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose up to approximately 6 months after first dose

  2. Breast Conserving Surgery (BCS) Rate

    The percentage of participants who undergo breast conserving surgery (BCS) after completing the study treatments. Confidence interval based on the Clopper and Pearson method.

    Time frame: From first dose up to approximately 6 months after first dose

  3. Pathological Complete Response (pCR) Rate

    The percentage of participants with an absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy. Confidence interval based on the Clopper and Pearson method.

    Time frame: From first dose up to approximately 6 months after first dose

  4. The Number of Participants Experiencing Adverse Events (AEs)

    The number of participants experiencing adverse events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 6 months)

  5. The Number of Participants Experiencing Serious Adverse Events (SAEs)

    The number of participants experiencing serious adverse events (SAEs). A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

    Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 6 months)

  6. The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

    The number of participants experiencing adverse events (AEs) that lead to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 6 months)

  7. The Number of Participants Experiencing Immune-Related Adverse Events (AEs)

    The number of participants experiencing adverse events that are immune-related. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 100 days after last dose of study therapy (up to approximately 8 months)

  8. The Number of Participants Deaths

    The number of participants that have died during the study.

    Time frame: From first dose up to approximately 8 months

  9. The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests - SI Units

    The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal

    Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 6 months)

  10. The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests

    The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal

    Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 6 months)

07

Results

Posted Aug 10, 2022
Limitations and caveats
Bristol Myers Squibb (BMS) decided to permanently discontinue enrollment and dosing in the nivolumab + abemaciclib + anastrozole cohorts during the Safety Run-in phase due to the risk of serious interstitial lung disease (ILD)/pneumonitis in patients receiving abemaciclib in combination with pembrolizumab. BMS decided to not move forward with the randomized phase of CA2097A8 and to close the trial after completion of the Safety Run-in.

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
Started2912
Completed136
Not completed166
Withdrew: Adverse event003
Withdrew: Participant request to discontinue study treatment001
Withdrew: Participant withdrew consent001
Withdrew: Other reasons100
Withdrew: Disease progression010
Withdrew: Study drug toxicity051

Outcome measures

PrimaryThe Number of Participants With Dose Limiting Toxicities (DLT) in the Safety Run-in Phase

The number of participants with dose limiting toxicities (DLTs) during the safety run-in phase. DLTS are defined as treatment emergent adverse events (TEAE) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 that occurs during the first 4 weeks (1 cycle) after treatment. Participants who withdraw from the study during the DLT evaluation period or have received less than 1 dose of nivolumab and 75% of accumulative doses of palbociclib of the cycle for reasons other than a DLT will not be considered as DLT-evaluable participants.

Time frame:
From first dose to 4 weeks after first dose
Reported as:
Count of participants · Participants
The Number of Participants With Dose Limiting Toxicities (DLT) in the Safety Run-in Phase
ParticipantsCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
The Number of Participants With Dose Limiting Toxicities (DLT) in the Safety Run-in Phase020
PrimaryResidual Cancer Burden (RCB) 0-1 Rate in the Randomized Phase

RCB 0-I rate is defined as the percentage of randomized participants who achieve RCB 0: no residual disease or RCB-I: minimal residual disease. RCB is a continuous index combining pathological measurements of primary tumor (size and cellularity) and nodal metastases (number and size) defined by a point system at surgery. No participants continued to the randomized phase; trial was closed after completion of the Safety Run-in.

Time frame:
From randomization phase up to 5 treatment cycles (up to approximately 20 weeks)

No measurements were reported for this outcome.

SecondaryObjective Response Rate (ORR)

ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per investigator radiographic assessment. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose up to approximately 6 months after first dose
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
Objective Response Rate (ORR)0.0 (0.0 to 84.2)66.7 (29.9 to 92.5)75.0 (42.8 to 94.5)
SecondaryBreast Conserving Surgery (BCS) Rate

The percentage of participants who undergo breast conserving surgery (BCS) after completing the study treatments. Confidence interval based on the Clopper and Pearson method.

Time frame:
From first dose up to approximately 6 months after first dose
Reported as:
Number · Percentage of Participants
Breast Conserving Surgery (BCS) Rate
Percentage of ParticipantsCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
Breast Conserving Surgery (BCS) Rate50.0 (1.3 to 98.7)55.6 (21.2 to 86.3)50.0 (21.1 to 78.9)
SecondaryPathological Complete Response (pCR) Rate

The percentage of participants with an absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy. Confidence interval based on the Clopper and Pearson method.

Time frame:
From first dose up to approximately 6 months after first dose
Reported as:
Number · Percentage of Participants
Pathological Complete Response (pCR) Rate
Percentage of ParticipantsCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
Pathological Complete Response (pCR) Rate0.0 (0.0 to 84.2)0.0 (0.0 to 33.6)8.3 (0.2 to 38.5)
SecondaryThe Number of Participants Experiencing Adverse Events (AEs)

The number of participants experiencing adverse events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 30 days after last dose of study therapy (up to approximately 6 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events (AEs)
ParticipantsCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
The Number of Participants Experiencing Adverse Events (AEs)2912
SecondaryThe Number of Participants Experiencing Serious Adverse Events (SAEs)

The number of participants experiencing serious adverse events (SAEs). A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Time frame:
From first dose to 30 days after last dose of study therapy (up to approximately 6 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Serious Adverse Events (SAEs)
ParticipantsCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
The Number of Participants Experiencing Serious Adverse Events (SAEs)052
SecondaryThe Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

The number of participants experiencing adverse events (AEs) that lead to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 30 days after last dose of study therapy (up to approximately 6 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
ParticipantsCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation054
SecondaryThe Number of Participants Experiencing Immune-Related Adverse Events (AEs)

The number of participants experiencing adverse events that are immune-related. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 100 days after last dose of study therapy (up to approximately 8 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Immune-Related Adverse Events (AEs)
ParticipantsCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
Hypothyroidism100
Hyperthyroidism001
Immune-mediated lung disease010
Pneumonitis001
Hepatitis032
Rash020
SecondaryThe Number of Participants Deaths

The number of participants that have died during the study.

Time frame:
From first dose up to approximately 8 months
Reported as:
Count of participants · Participants
The Number of Participants Deaths
ParticipantsCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
The Number of Participants Deaths000
SecondaryThe Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests - SI Units

The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal

Time frame:
From first dose to 30 days after last dose of study therapy (up to approximately 6 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests - SI Units
ParticipantsCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
TSH > ULN132
TSH > ULN WITH TSH <= ULN AT BASELINE121
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN012
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN022
TSH > ULN WITH FT3/FT4 TEST MISSING100
TSH < LLN034
TSH <LLN WITH TSH >= LLN AT BASELINE024
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN011
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN013
TSH < LLN WITH FT3/FT4 TEST MISSING010
SecondaryThe Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests

The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal

Time frame:
From first dose to 30 days after last dose of study therapy (up to approximately 6 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests
ParticipantsCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
ALT OR AST > 3XULN043
ALT OR AST > 5XULN033
ALT OR AST > 10XULN022
ALT OR AST > 20XULN012
TOTAL BILIRUBIN > 2XULN000
ALP > 1.5XULN031
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 1 DAY011
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 30 DAYS011
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY000
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS000

Adverse events

Collected over Adverse Events (AEs) were monitored from first dose to 100 days after last dose of study therapy (up to approximately 8 months). Serious Adverse events were monitored between first dose and 30 days after last dose of study therapy. (Up to approximately 6 months) Participants were assessed for All Cause Mortality from their first dose until the study was completed (up to approximately 21 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Dose Level 10/2 (0%)0/2 (0%)2/2 (100%)
Cohort 2: Dose Level 10/9 (0%)5/9 (55.6%)8/9 (88.9%)
Cohort 2: Dose Level 20/12 (0%)3/12 (25%)12/12 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
AnaemiaBlood and lymphatic system disorders0/21/90/12
Febrile neutropeniaBlood and lymphatic system disorders0/21/90/12
Atrial fibrillationCardiac disorders0/21/90/12
HepatitisHepatobiliary disorders0/21/90/12
Alanine aminotransferase increasedInvestigations0/21/90/12
Aspartate aminotransferase increasedInvestigations0/21/90/12
Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders0/21/90/12
RashSkin and subcutaneous tissue disorders0/21/90/12
HypertransaminasaemiaHepatobiliary disorders0/20/91/12
Second primary malignancyNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/20/91/12
Most frequent other events
Showing 10 of 85
Most frequent other events
EventCohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2
PruritusSkin and subcutaneous tissue disorders2/21/93/12
HypothyroidismEndocrine disorders1/20/91/12
Vision blurredEye disorders1/20/90/12
Abdominal painGastrointestinal disorders1/20/91/12
DiarrhoeaGastrointestinal disorders1/22/91/12
NauseaGastrointestinal disorders1/21/91/12
VomitingGastrointestinal disorders1/20/91/12
FatigueGeneral disorders1/22/95/12
GastroenteritisInfections and infestations1/20/90/12
Upper respiratory tract infectionInfections and infestations1/20/90/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2Total
Mean63 ± 2.860.3 ± 9.367.4 ± 10.264.3 ± 9.8
Age, Customized
Age, Customized(Participants)Cohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2Total
< 6517513
>= 65 AND < 751135
>= 75 AND < 850145
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2Total
Female291223
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2Total
Hispanic or Latino0224
Not Hispanic or Latino25714
Unknown or Not Reported0235
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Dose Level 1Cohort 2: Dose Level 1Cohort 2: Dose Level 2Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White191121
More than one race0000
Unknown or Not Reported1001
08

Study locations

36 sites
  • Local Institution - 0031
    Whittier, California 90603, United States
  • University Cancer Blood Ctr
    Athens, Georgia 30607, United States
  • Northside Hospital,Inc.- Central Research Department
    Atlanta, Georgia 30342, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Local Institution - 0041
    Florham Park, New Jersey 07932, United States
  • The Cancer Center At Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • Hematology-Oncology Associates Of Fredricksburg, Inc
    Fredericksburg, Virginia 22408, United States
  • Peninsula Cancer Institute
    Newport News, Virginia 23601, United States
  • Local Institution - 0005
    Elizabeth Vale, South Australia 5112, Australia
  • Breast Cancer Research Centre - WA
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0011
    Wilrijk, Antwerpen 2610, Belgium
  • Local Institution
    Liege, 4000, Belgium
  • Local Institution
    Namur, 5000, Belgium
  • Local Institution - 0071
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution - 0075
    Bordeaux, 33077, France
  • Local Institution - 0073
    Creteil Cedex, 94010, France
  • Local Institution - 0072
    La Roche-sur-yon Cedex 9, 85925, France
  • Centre Leon Berard
    Lyon Cedex 08, 69373, France
  • Local Institution - 0019
    Marseille Cedex 9, 13273, France
  • Centre de Cancerologie du Grand Montpellier
    Montpellier, 34070, France
  • Institut Claudius Regaud
    TOULOUSE Cedex 9, 31059, France
  • Local Institution
    Bonn, 53111, Germany
  • Local Institution
    Erlangen, 91054, Germany
  • Klinik Essen-Mitte
    Essen, 45136, Germany
  • Local Institution
    Moenchengladbach, 41061, Germany
  • Local Institution
    Saarbruecken, 66113, Germany
  • Local Institution - 0047
    Monterrey Ponce, 00731, Puerto Rico
  • Local Institution - 0002
    San Juan, 00927, Puerto Rico
  • Local Institution - 0062
    San Juan, 00936, Puerto Rico
  • H. Univ. Vall dHebron
    Barcelona, 08035, Spain
  • Local Institution - 0037
    Barcelona, 08036, Spain
  • Hosp Univer 12 De Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Virgen De La Victoria
    Malaga, 29010, Spain
  • Hospital Universitario Virgen Del Rocio
    Sevilla, 41013, Spain
  • Hospital Clinico Universitario De Valencia
    Valencia, 46010, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jul 2021, 21 months.

Results were first posted in Aug 2022, 1 year after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 21 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2019
First posted
Sep 3, 2019
StartActual
Oct 18, 2019
Primary completionActual
Jul 27, 2021
CompletionActual
Jul 27, 2021
Results first posted
Aug 10, 2022
Last update
Aug 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04075604
Responsible party
Sponsor
First posted
Sep 3, 2019
Start date
Oct 18, 2019
Primary completion
Jul 27, 2021
Completion
Jul 27, 2021
Results posted
Aug 10, 2022
Last update
Aug 10, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion